Melanoma Brain Metastases Patient-Derived Organoids: An In Vitro Platform for Drug Screening

被引:0
|
作者
Abedellatif, Saif-Eldin [1 ]
Hosni, Racha [1 ]
Waha, Andreas [2 ]
Gielen, Gerrit H. [2 ]
Banat, Mohammed [3 ]
Hamed, Motaz [3 ]
Gueresir, Erdem [3 ]
Froehlich, Anne [4 ]
Sirokay, Judith [4 ]
Wulf, Anna-Lena [1 ]
Kristiansen, Glen [1 ]
Pietsch, Torsten [2 ]
Vatter, Hartmut [3 ]
Hoelzel, Michael [5 ]
Schneider, Matthias [3 ]
Toma, Marieta Ioana [1 ]
机构
[1] Univ Hosp Bonn, Inst Pathol, D-53127 Bonn, Germany
[2] Univ Hosp Bonn, Inst Neuropathol, D-53127 Bonn, Germany
[3] Univ Hosp Bonn, Dept Neurosurg, D-53127 Bonn, Germany
[4] Univ Hosp Bonn, Dept Dermatol, D-53127 Bonn, Germany
[5] Univ Hosp Bonn, Inst Expt Oncol, Bonn, Germany
关键词
melanoma; brain metastases; BRAF; organoids; DABRAFENIB;
D O I
10.3390/pharmaceutics16081042
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and aims: Brain metastases are prevalent in the late stages of malignant melanoma. Multimodal therapy remains challenging. Patient-derived organoids (PDOs) represent a valuable pre-clinical model, faithfully recapitulating key aspects of the original tumor, including the heterogeneity and the mutational status. This study aimed to establish PDOs from melanoma brain metastases (MBM-PDOs) and to test the feasibility of using them as a model for in vitro targeted-therapy drug testing. Methods: Surgical resection samples from eight patients with melanoma brain metastases were used to establish MBM-PDOs. The samples were enzymatically dissociated followed by seeding into low-attachment plates to generate floating organoids. The MBM-PDOs were characterized genetically, histologically, and immunohistologically and compared with the parental tissue. The MBM-PDO cultures were exposed to dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) followed by a cell viability assessment. Results: Seven out of eight cases were successfully cultivated, maintaining the histological, immunohistological phenotype, and the mutational status of the parental tumors. Five out of seven cases harbored BRAF V600E mutations and were responsive to BRAF and MEK inhibitors in vitro. Two out of seven cases were BRAF wild type: one case harboring an NRAS mutation and the other harboring a KIT mutation, and both were resistant to BRAF and MEK inhibitor therapy. Conclusions: We successfully established PDOs from melanoma brain metastases surgical specimens, which exhibited a consistent histological and mutational profile with the parental tissue. Using FDA-approved BRAF and MEK inhibitors, our data demonstrate the feasibility of employing MBM-PDOs for targeted-therapy in vitro testing.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Patient-Derived Organoids as Therapy Screening Platforms in Cancer Patients
    Khorsandi, Danial
    Yang, Jia-Wei
    Foster, Samuel
    Khosravi, Safoora
    Hosseinzadeh Kouchehbaghi, Negar
    Zarei, Fahimeh
    Lee, Yun Bin
    Runa, Farhana
    Gangrade, Ankit
    Voskanian, Leon
    Adnan, Darbaz
    Zhu, Yangzhi
    Wang, Zhaohui
    Jucaud, Vadim
    Dokmeci, Mehmet Remzi
    Shen, Xiling
    Bishehsari, Faraz
    Kelber, Jonathan A.
    Khademhosseini, Ali
    de Barros, Natan Roberto
    ADVANCED HEALTHCARE MATERIALS, 2024, 13 (21)
  • [42] Rapid and scalable personalized ASO screening in patient-derived organoids
    John C. Means
    Anabel L. Martinez-Bengochea
    Daniel A. Louiselle
    Jacqelyn M. Nemechek
    John M. Perry
    Emily G. Farrow
    Tomi Pastinen
    Scott T. Younger
    Nature, 2025, 638 (8049) : 237 - 243
  • [43] An automated platform for rapid drug screening in patient-derived micro-organospheres
    Wang, Z.
    Cortes-Sanchez, E.
    Yang, C-H.
    Nelson, D.
    Keating, C.
    Smith, A.
    Hsu, D.
    Welm, B.
    Welm, A.
    Shen, X.
    ANNALS OF ONCOLOGY, 2021, 32 : S929 - S929
  • [44] Patient-Derived Organoids of Cholangiocarcinoma
    Maier, Christopher Fabian
    Zhu, Lei
    Nanduri, Lahiri Kanth
    Kuehn, Daniel
    Kochall, Susan
    Thepkaysone, May-Linn
    William, Doreen
    Grutzmann, Konrad
    Klink, Barbara
    Betge, Johannes
    Weitz, Jurgen
    Rahbari, Nuh N.
    Reissfelder, Christoph
    Schoelch, Sebastian
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (16)
  • [45] Patient-derived organoids of non-small cells lung cancer and their application for drug screening
    Li, Y. F.
    Gao, Y.
    Liang, B. W.
    Cao, X. Q.
    Sun, Z. J.
    Yu, J. H.
    Liu, Z. D.
    Han, Y.
    NEOPLASMA, 2020, 67 (02) : 430 - +
  • [46] PERSONALIZED DRUG SCREENING IN PATIENT-DERIVED ORGANOIDS OF BILIARY TRACT CANCER AND ITS CLINICAL APPLICATION
    Ren, Xiaoxue
    Wu, Yifan
    Huang, Mingle
    Li, Xiaoxing
    Yu, Jun
    Xu, Lixia
    GASTROENTEROLOGY, 2023, 164 (06) : S1255 - S1255
  • [47] Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening
    Matteo Boretto
    Nina Maenhoudt
    Xinlong Luo
    Aurélie Hennes
    Bram Boeckx
    Bich Bui
    Ruben Heremans
    Lisa Perneel
    Hiroto Kobayashi
    Indra Van Zundert
    Hilde Brems
    Benoit Cox
    Marc Ferrante
    Hiroshi Uji-i
    Kian Peng Koh
    Thomas D’Hooghe
    Arne Vanhie
    Ignace Vergote
    Christel Meuleman
    Carla Tomassetti
    Diether Lambrechts
    Joris Vriens
    Dirk Timmerman
    Hugo Vankelecom
    Nature Cell Biology, 2019, 21 : 1041 - 1051
  • [48] Medium-Throughput Drug- and Radiotherapy Screening Assay using Patient-Derived Organoids
    Putker, Marrit
    Millen, Rosemary
    Overmeer, Rene
    Driehuis, Else
    Zandvliet, Maurice M. J. M.
    Clevers, Hans
    Boj, Sylvia F.
    Li, Qi-Xiang
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2021, (170):
  • [49] Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application
    Ren, Xiaoxue
    Huang, Mingle
    Weng, Weixiang
    Xie, Yubin
    Wu, Yifan
    Zhu, Shenghua
    Zhang, Ying
    Li, Dongming
    Lai, Jiaming
    Shen, Shunli
    Lin, Jie
    Kuang, Ming
    Li, Xiaoxing
    Yu, Jun
    Xu, Lixia
    CELL REPORTS MEDICINE, 2023, 4 (11)
  • [50] Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening
    Boretto, Matteo
    Maenhoudt, Nina
    Luo, Xinlong
    Hennes, Aurelie
    Boeckx, Bram
    Bui, Bich
    Heremans, Ruben
    Perneell, Lisa
    Kobayashi, Hiroto
    Van Zundert, Indra
    Brems, Hilde
    Cox, Benoit
    Ferrante, Marc
    Uji-i, Hiroshi
    Koh, Kian Peng
    D'Hooghe, Thomas
    Vanhie, Arne
    Vergote, Ignace
    Meuleman, Christel
    Tomassetti, Carla
    Lambrechts, Diether
    Vriens, Joris
    Timmerman, Dirk
    Vankelecom, Hugo
    NATURE CELL BIOLOGY, 2019, 21 (08) : 1041 - +